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Therapeutic angiogenesis by growth factor delivery is an attractive treatment strategy for ischemic 
diseases, yet clinical efficacy has been elusive. The angiogenic master regulator VEGF-A can induce 
aberrant angiogenesis if expressed above a threshold level. Since VEGF remains localized in the 
matrix around expressing cells, homogeneous dose distribution in target tissues is required, which is 
challenging. We found that co-expression of the pericyte-recruiting factor PDGF-BB at a fixed ratio 
with VEGF from a single bicistronic vector ensured normal angiogenesis despite heterogeneous high 
VEGF levels. Taking advantage of a highly controlled gene delivery platform, based on monoclonal 
populations of transduced myoblasts, in which every cell stably produces the same amount of each 
factor, here we rigorously investigated a) the dose-dependent effects, and b) the long-term safety 
and stability of VEGF and PDGF-BB co-expression in skeletal muscle. PDGF-BB co-expression did not 
affect the normal angiogenesis by low and medium VEGF doses, but specifically prevented vascular 
tumors by high VEGF, yielding instead normal and mature capillary networks, accompanied by robust 
arteriole formation. Induced angiogenesis persisted unchanged up to 4 months, while no tumors 
appeared. Therefore, PDGF-BB co-expression is an attractive strategy to improve safety and efficacy of 
therapeutic angiogenesis by VEGF gene delivery.
Coronary and peripheral artery diseases are still a major cause of morbidity and mortality in Western countries 
despite optimal medical and surgical treatment1. Therapeutic angiogenesis, i.e. the growth of new blood vessels 
by the delivery of specific growth factors in order to restore the perfusion of tissue distal to a vascular occlusion, 
is an attractive strategy to fill this unmet clinical need. Vascular endothelial growth factor-A (VEGF) is the master 
regulator of vascular growth in both physiological and pathological conditions2. However, it has been shown that 
the uncontrolled delivery of VEGF to both ischemic and non-ischemic tissues by a variety of methods causes 
excessive vascular proliferation, with the growth of aberrant vessels and angioma-like vascular tumors3–8. Since 
VEGF164 remains tightly bound to the extracellular matrix9, the induction of normal or aberrant angiogenesis 
has been found to depend on the concentration of VEGF in the microenvironment around each producing cell 
in vivo, rather than its total dose, both in normal and ischemic muscle10,11. When microenvironmental concentra-
tions are homogeneously distributed in the tissue, a range of doses yields only morphologically normal capillaries, 
whereas angioma-like vascular structures are induced above a distinct threshold level10. However we recently 
found that the transition between normal and aberrant angiogenesis does not depend exclusively on VEGF dose, 
but rather on the balance between endothelial stimulation by VEGF and pericyte recruitment by Platelet-derived 
growth factor-BB (PDGF-BB)12. In fact, when endogenous PDGF-BB signaling was blocked, even low VEGF 
levels caused angioma-like vascular structures and, conversely, balanced co-expression of both factors from a 
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single bicistronic vector prevented aberrant angiogenesis by uncontrolled and high VEGF levels, yielding instead 
only mature and morphologically normal capillary networks after 2 weeks, which significantly improved blood 
flow and collateral growth in a mouse model of hindlimb ischemia12. In agreement with these findings, VEGF and 
PDGF-BB co-delivery by AAV vectors significantly improved the functional efficacy of VEGF alone in ischemic 
models both in rabbit hindlimb and pig myocardium, while enabling a 5-fold vector dose reduction13. Also, 
sequential release of the two recombinant factors from hydrogels in ischemic mouse myocardium could increase 
the induction of mature arteriole-like vessels, without affecting capillary growth, leading to improved cardiac 
function14.
Based on these results, balanced co-expression of VEGF and PDGF-BB is a promising strategy to overcome the 
limitations of VEGF gene delivery in pro-angiogenic therapeutic approaches. However, it is currently unknown: 
1) whether and how PDGF-BB co-expression may modify the angiogenic responses induced by specific VEGF 
doses; and 2) the safety of long-term co-expression of VEGF and PDGF-BB in a therapeutically relevant range 
of doses. A major hurdle has been the paucity of tools available to precisely control the amount of both factors 
in the microenvironment around each producing cell in vivo. Therefore, here we took advantage of a highly con-
trolled platform for sustained gene expression in skeletal muscle that we developed in the last decade10,15, based 
on monoclonal populations of transduced myoblasts, in which every cell stably produces a specific amount of 
VEGF alone or at a fixed ratio with PDGF-BB, to rigorously investigate a) the dose-dependent effects, and b) the 
long-term safety and stability of angiogenesis induced by balanced and constitutive co-expression of VEGF and 
PDGF-BB in the therapeutic target tissue of skeletal muscle.
Results
Generation, in-vitro characterization and selection of  V, P and VIP myoblast clones. Primary 
mouse myoblasts were transduced with a bicistronic retroviral vector (named pAMFG-VIP for Vegf-IRES-Pdgfb) 
expressing murine VEGF164 and human PDGF-BB at a fixed relative ratio, as previously described12. To rigorously 
study the dose-dependent effects of PDGF-BB co-expression on VEGF-induced angiogenesis, a pool of 90 mono-
clonal populations was isolated from the VIP polyclonal myoblasts (VIP clones). VEGF and PDGF-BB expression 
were measured by ELISA in all clones and they were found to cover a wide range of levels (VEGF: 3.0 ± 0.3 to 
158.5 ± 2.3 ng/106 cells/day; PDGF-BB: 0.2 ± 0.0 to 33.0 ± 0.4 ng/106 cells/day). The ratio of PDGF-BB:VEGF164 
production in individual clones was of 0.36 ± 0.02 on a molar basis with a very high correlation coefficient of 
R2 = 0.9 (Fig. 1a), showing that the two factors were produced at a fixed ratio in each individual cell, regardless 
of the absolute amounts. A similar pool of 20 monoclonal populations expressing only PDGF-BB (P clones) 
was isolated from myoblasts transduced with a retrovirus carrying the Pdgfb sequence alone. The PDGF-BB 
production of P clones ranged from 0.8 ± 0.03 to 28.7 ± 1.3 ng/106cells/day, covering the same spectrum as the 
VIP clones. A previously generated library of 21 VEGF-expressing monoclonal populations10,11,15 produced only 
murine VEGF164 in a range between 0.8 ± 0.1 and 191.2 ± 13.5 ng/106cells/day (V clones), also covering a similar 
spectrum as the VIP clones. Based on their in vitro production of VEGF, three groups of two VIP clones each were 
Figure 1. Balanced VEGF and PDGF-BB expression by VIP myoblast clones and selection of clone 
families. (a) Correlation between in vitro production of VEGF164 and PDGF-BB (in ng/106 cells/day) in 90 
individual myoblast VIP clones, co-expressing the two factors from a single bicistronic retroviral vector. The 
relative levels were linearly correlated in each clone (R2 = 0.9). (b–d) Based on their in vitro production of VEGF 
and/or PDGF-BB, 6 VIP clones were paired to 6 V clones and 5 P clones, expressing only VEGF and PDGF-BB 
respectively, in 3 different groups of increasing expression levels (Low, Medium and High). Data are shown as 
mean ± SEM (n = 4/clone).
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selected: VIP-low (VEGF range: 5–15 ng/106 cells/day), VIP-medium (VEGF range: 30–70 ng/106 cells/day) and 
VIP-high (VEGF range: > 100 ng/106 cells/day) (Fig. 1b–d). Each group was paired with two V and two P clones, 
selected from the libraries described above and secreting equivalent amounts of either VEGF or PDGF-BB alone 
(except for the high PDGF-BB group, where only one clone was available) (Fig. 1b–d). All retroviral vectors also 
expressed a truncated version of CD8a as a convenient FACS-sortable cell surface marker15 and cells transduced 
with the empty retroviral vector expressing only CD8a (control cells) were used as negative control.
PDGF-BB co-expression prevents aberrant angiogenesis by high VEGF levels, but does not 
affect vessel quantity nor size by low and medium VEGF. To determine whether and how PDGF-BB 
co-expression modified the effects of specific microenvironmental VEGF doses, vascular morphology was eval-
uated 4 weeks after implantation of the selected VIP, V and P clones in the ear muscle (auricularis posterior) of 
SCID mice. The thin and accessible muscle layer in the dorsal aspect of the external mouse ear is ideally suited 
to whole-mount analysis of morphological changes in vascular networks: myoblast engraftment was detected 
by X-gal staining and vascular morphology was visualized by intravascular lectin staining, as previously estab-
lished10. Control CD8 cells and all P clones (represented here for convenience only by the highest PDGF-BB 
producer, P-high) did not alter the pre-existing vasculature, made up mostly of homogeneous capillaries run-
ning parallel to the muscle fibers (Fig. 2a–c; n = 6 control cells, n = 5–10 for each P clone). As expected10,15, low 
and medium V clones induced only normal angiogenesis, made up of homogeneous capillary-sized microves-
sels, whereas V-high clones caused the appearance of large angioma-like vascular structures, characterized by 
the bulb-like and progressive circumferential enlargement of discrete vessel segments of heterogeneous sizes 
(Fig. 2d–f; n = 8). All the VIP clones, which belonged to the specific groups of VEGF expression, induced vessels 
of morphology that did not differ between each other. PDGF-BB co-expression did not qualitatively affect the 
normal angiogenesis induced by low and medium VEGF levels (VIP-low and VIP-med clones), yielding normal 
capillaries that wrapped around each single transduced muscle fiber (Fig. 2g,h; n = 8). Remarkably, the VIP-high 
clones induced only dense networks of morphologically normal capillaries, with no instances of angioma-like 
structures, despite high levels of VEGF expression (Fig. 2i; n = 10).
The amount of induced vascularity was quantified by measuring the vessel length density (VLD), corre-
sponding to the total vascular length in a given area independent of vessel size or morphology (Fig. 3a). All 
PDGF-BB levels (P-low, P-med and P-high clones) did not induce any angiogenesis and VLD in the implan-
tation areas did not increase compared to control cells, as expected (62.5 ± 1.5 mm/mm2, 63.1 ± 2.3 mm/mm2 
and 62.5 ± 1.5 mm/mm2, respectively; control cells = 67.3 ± 5.1 mm/mm2). Since the results were similar 
between the three PDGF-BB doses, only the VLD of the P-high condition is shown in Fig. 3a. Low and medium 
V clones induced a marked increase in VLD compared to control cells (118.7 ± 2.7 and 119.9 ± 1.2 mm/mm2, 
respectively; p < 0.0001), but PDGF-BB co-expression did not further increase the amount of angiogenesis 
(VIP-low = 114.4 ± 2.5, VIP-med = 116.2 ± 2.3 mm/mm2, p = N.S. vs the corresponding V clones). On the other 
hand, high VEGF levels did not increase VLD compared to controls (62.5 ± 2.6 mm/mm2, p = N.S.), because the 
induced aberrant angiogenesis comprised almost exclusively circumferentially enlarged bulbous vascular seg-
ments, which did not contribute significant increases to the vascular length of the network (Fig. 2f). However, 
PDGF-BB co-expression with high VEGF levels significantly increased VLD compared with VEGF alone 
(VIP-high = 121.7 ± 2.5 mm/mm2 vs V-high = 62.5 ± 2.6 mm/mm2, p < 0.0001), restoring it to values similar to 
those obtained with low and medium VEGF levels, as the angioma-like vascular structures were replaced by 
normal capillary networks (Fig. 2i).
Further, vessel diameters were measured on randomly selected fields using a standardized grid overlay 
and were shown as average values ± SEM (Fig. 3b) or size distributions (Fig. 3c). Pre-existing normal capillar-
ies in areas implanted with control CD8 cells had homogeneous sizes, tightly distributed around a median of 
5.6 μ m and with a 90th percentile value of 10 μ m. Surprisingly PDGF-BB induced a moderate enlargement of the 
pre-existing capillaries, with an apparent dose-dependent trend, which however was not significant (median of 
6.8 μ m, 7.2 μ m and of 7.5 μ m for P-low, P-med and P-high, respectively; only the P-high condition is shown in 
Fig. 3b,c). New vessels induced by V-low and V-med clones had homogeneous capillary-like size distributions, but 
a VEGF dose-dependent increase in diameters was observed (median = 5.8 μ m and 7 μ m for V-low and V-med, 
respectively; p < 0.05 in Fig. 3b), as previously described11, whereas high levels of VEGF alone generated vascular 
structures with very heterogeneous diameters, 20.4% of which were larger than 15 μ m (90th percentile = 35.9 μ m; 
p < 0.0001 in Fig. 3b). PDGF-BB co-expression did not significantly change the size of vessels induced by equiv-
alent doses of VEGF alone in the range inducing normal angiogenesis, despite a slight increase in the median 
value of diameter distributions (6.2 μ m and 7.5 μ m for VIP-low and VIP-medium, respectively). The completely 
normal angiogenesis induced by PDGF-BB co-expression with high VEGF levels (VIP-high) was comprised of 
homogeneous capillary-size micro-vascular networks (90th percentile = 9.7 μ m with only 0.8% of vessels larger 
than 15 μ m). Interestingly, the diameters of these normalized vessels were not further increased compared to the 
V-med/VIP-med conditions (median = 7.2 μ m; p = N.S. in Fig. 3b), suggesting that the VEGF dose-dependent 
increase in the size of new vessels is limited to a maximum value compatible with normal angiogenesis.
Vascular maturation. Vascular maturation was investigated by assessing pericyte coverage of the induced 
endothelial structures. Pre-existing capillaries in muscles treated with control cells and all PDGF-expressing 
groups (P-low, P-med and P-high), in which no angiogenesis was induced, were uniformly covered with typical 
pericytes, staining positive for nerve/glial antigen 2 (NG2) and negative for α -SMA (Fig. 4a,b; n = 6 for control 
cells and n = 2–3 for each P group). Remarkably, in all muscles implanted with P clones NG2-positive pericytes 
could only be observed in close contact with endothelial structures, but not in the interstitial spaces among 
the myofibers, showing that sustained PDGF-BB expression did not lead to excessive pericyte proliferation. As 
previously described, newly induced capillaries by both low and medium VEGF were also invested by normal 
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NG2-positive pericytes (Fig. 4c,e), whereas high VEGF caused the appearance of large angioma-like aberrant vas-
cular structures, devoid of pericytes and associated with a typical coverage of NG2-negative and α -SMA-positive 
smooth muscle cells (Fig. 4g). PDGF-BB co-expression with low or medium VEGF levels (VIP-low and VIP-med) 
not only did not affect the maturation of the normal capillaries that were induced, which were uniformly covered 
with NG2-positive pericytes, but also did not cause proliferation and accumulation of additional NG2-positive 
cells in the interstitial spaces between muscle fibers at either level of expression (Fig. 4d,f). In agreement with the 
results in the ear muscle (Fig. 2), PDGF-BB co-expression caused complete morphological normalization of the 
vasculature induced by high VEGF levels (VIP-high) in limb muscles as well. Such normalized capillary networks 
displayed a physiological association with NG2-positive pericytes instead of the thick smooth muscle coating 
of angioma-like structures generated by the same doses of VEGF alone. Again, no additional NG2-positive or 
α -SMA-positive cells were found outside of vessel walls in the interstitial spaces between muscle fibers (Fig. 4h).
In vivo expression kinetics of delivered and endogenous VEGF and PDGF-BB. The specific 
monoclonal populations of transduced myoblasts were selected on the basis of their transgene expression levels 
Figure 2. PDGF-BB co-expression switches aberrant angiogenesis by high VEGF doses to normal.  
(a–i) Control myoblasts (Ctrl) or myoblast clones expressing VEGF (V), PDGF-BB (P) or both (VIP) at low, 
medium or high levels were implanted into the ear muscles of SCID mice. Four weeks later, vascular morphology 
was analyzed in tissue whole-mounts by intravascular lectin staining (brown) and myoblast engraftment was 
revealed by X-Gal staining (blue; n = 5–10 samples/group). Asterisks indicate angioma-like aberrant vascular 
structures. Size bars = 20 μ m.
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measured in vitro. However, if VEGF expression by the VIP clones were lost in vivo more than that by the equiv-
alent V clones, particularly during the crucial initial stages of vascular induction, this would lead to a lower 
effective VEGF production in the tissue and could potentially explain the lack of aberrant angiogenesis even 
without a functional effect of PDGF-BB. Therefore, we sought to verify this possibility by quantifying in vivo gene 
expression by qRT-PCR in calf muscles four and seven days after implantation of V and VIP clones expressing 
medium and high VEGF levels, as the switch between normal and aberrant angiogenesis, as well as its reversal by 
PDGF-BB co-expression, takes place between these doses. These time-points were chosen because we previously 
found that the morphogenic events leading to either normal or aberrant structures by increasing VEGF doses 
take place between four and seven days after implantation, while no new vascular growth takes place afterwards16. 
Gene expression analysis with specific primers for the viral vector-encoded factors confirmed that in vivo expres-
sion of Vegfa from VIP clones was similar or higher than that of equivalent V clones at both time-points (Fig. 5a). 
As expected, expression of delivered human Pdgfb also remained higher with the VIP-high clone compared to 
the VIP-med clone at both time points (Fig. 5b). Expression of the endogenous Vegfa and Pdgfb genes was also 
quantified, using specific primers spanning the 5′ -UTR sequence of the murine Vegfa mRNA, which is absent in 
the retroviral cassette, and a commercial assay specific for murine Pdgfb, respectively. Endogenous Vegfa was not 
affected by V clones, but was up-regulated by both VIP clones at both four and seven days (Fig. 5c). Endogenous 
Pdgfb was up-regulated by all clones at four days and expression declined by seven days, consistently with the 
transient activation of endothelium during the initial stage of angiogenesis. However, it remained similarly and 
slightly elevated compared to baseline in both V-high and VIP-high conditions (Fig. 5d).
Long-term persistence and vascular maturation. In order to be therapeutically useful, the newly 
induced vasculature needs to: a) persist in the long-term, to ensure efficacy, and b) avoid progressive uncon-
trolled growth, even of morphologically normal capillary networks, to ensure safety. We therefore studied the 
long-term fate of the newly formed vasculature induced by VEGF and PDGF-BB co-expression up to 4 months 
after cell implantation, both in the ear and leg muscles. Control cells fused into muscle fibers and still persisted 
after 4 months, as shown by X-gal staining, while the morphology of pre-existing vasculature was not altered 
(Fig. 6a,b). Since expression of PDGF-BB alone did not induce any angiogenesis by 4 weeks at any dose, this 
group was not repeated. The normal capillary networks induced by V-low and V-med clones persisted unchanged 
(Fig. 6c,d), whereas high VEGF levels alone (V-high) caused the aberrant enlarged structures induced by 
4 weeks to develop into large macroscopic cavernous angiomas already after 6 and 9 weeks in the ear and leg 
muscles respectively, which required early termination of the experiment for this group (Fig. 6e). Co-expression 
Figure 3. PDGF-BB co-expression does not affect normal angiogenesis by low and medium doses of VEGF 
alone. (a) The amount of angiogenesis was quantified by measuring vessel length density in areas of myoblast 
engraftment on tissue whole-mounts after intravascular lectin staining (n = 10–18 measurements/group in 
5–10 tissues/group). (b,c) Vessel diameters (in μ m) were quantified in the same areas (n > 200/group in 5–10 
tissues/group) and results are shown as mean ± SEM (b) and as the distribution of vessel diameters over 1-μ m 
intervals (c) VLD = vessel length density (mm of vessel length/mm2 of area of effect); *p < 0.05, **p < 0.01 and 
****p < 0.0001 (ANOVA with Sidak multiple comparisons test).
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of PDGF-BB with low and medium VEGF levels did not modify the normal morphology of newly induced cap-
illaries compared to the 4 week time-point (Fig. 6f,g). The normalized capillary networks induced by high-level 
co-expression (VIP-high) also remained stable and did not progress towards angioma-like structures (Fig. 6h). 
Figure 4. PDGF-BB co-expression restores normal pericyte coverage of vessels induced by high VEGF.  
V, VIP and P myoblast clones, expressing low, medium or high levels of one or both factors, as well as control cells 
(Ctrl), were implanted into calf muscles of SCID mice. Frozen sections were obtained 4 weeks after implantation 
and immunostained for CD31 (endothelium, in red), NG2 (pericytes, in green) and α -SMA (smooth muscle 
cells, in cyan); n = 3–8 samples/group. In each panel, the right image is a higher-magnification view of the area 
marked by the white dotted box in the left image. Size bars = 20 μ m; asterisks indicate angioma-like aberrant 
vascular structures.
www.nature.com/scientificreports/
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The quantification of vessel length density showed that, in all conditions leading to morphologically normal 
capillaries (V-low, V-med, VIP-low, VIP-med and VIP-high), induced vessels neither regressed nor increased in 
quantity over 4 months, despite continued expression of the transgenes, as determined by the persistence of the 
β -gal marker production (blue fibers in Fig. 6). Rather, vessel quantities were stable compared to the 4-week time 
point (Fig. 3a), similar in all conditions and about double compared with controls (V-low = 119.8 ± 2.6 mm/mm2; 
V-med =  116.1 ±  1.5 mm/mm2; VIP-low =  117.2 ±  2.6 mm/mm2; VIP-med =  120.4 ±  2.2 mm/mm2; 
VIP-high = 123.6 ± 2.4 mm/mm2; Controls = 66.6 ± 2.0 mm/mm2; Fig. 6i).
The long-term maturation of induced vasculature was analysed by immunostaining on frozen sections of 
leg muscles 4 months after cell implantation. All morphologically normal capillary networks induced by V-low, 
V-med, VIP-low, VIP-med and VIP-high conditions were uniformly associated with NG2-positive pericytes 
(Fig. 7b–e,g), similarly to the normal pre-existing capillaries in muscles implanted with control cells (Fig. 7a). 
The large angiomas induced by V-high cells lacked pericytes, but were covered by a thick smooth muscle coat, 
as expected (Fig. 7f). Remarkably, no accumulation or expansion of NG2-positive cells, beyond the individual 
pericytes associated with vessels, was observed in any of the muscles, even in the PDGF-BB-overexpressing con-
ditions (Fig. 7c,e,g). X-gal staining showed that implanted myoblasts stably engrafted along the needle tracks in 
muscles 4 months after injection (Fig. 8). In all conditions that induced normal angiogenesis (V-low, V-med, 
VIP-low, VIP-med and VIP-high) and in control tissues myoblast engraftment was similar, consisting both 
of fusion to pre-existing large fibers and of differentiation into smaller-caliber de novo fibers (Fig. 8a–c,e–g). 
Consistently with previous observations10 and with the results in the ear muscles after 4 weeks (Fig. 2f), no myo-
blasts survived in the V-high condition after 9 weeks (Fig. 8d).
Dose-dependent arteriole formation. Functional vascular networks comprise both microvascu-
lar capillaries, responsible for nutrient and respiratory gases exchange, and larger caliber arterioles, capable of 
supplying increased blood flow and responsible for regulating perfusion of downstream capillaries depending 
on the metabolic needs of the tissue. Therefore, we identified arterioles in implanted muscles 4 months after 
myoblast injection as regularly shaped vessels, moderately larger than capillaries (15–30 μ m) and covered by a 
Figure 5. In vivo expression of delivered and endogenous factors. In vivo expression of the Vegfa and Pdgfb 
genes, discriminating between the delivered and endogenous transcripts, was quantified in calf muscles 4 and 7 
days after implantation with control cells (Ctrl) and myoblast clones expressing medium or high levels of VEGF 
alone or with PDGF-BB (V and VIP, respectively). Data are shown as mean ± SEM (n = 4 muscles/condition); 
*p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 (ANOVA with Sidak multiple comparisons test after data 
normalization by logarithmic transformation).
www.nature.com/scientificreports/
8Scientific RepoRts | 6:21546 | DOI: 10.1038/srep21546
Figure 6. Normal vasculature induced by VEGF and PDGF-BB co-expression persists unchanged up to 4 
months. (a–h) Control cells (Ctrl) or V and VIP myoblast clones expressing low, medium or high levels were 
implanted into the ear muscles of SCID mice. Four months later, vascular morphology was analyzed in tissue 
whole-mounts by intravascular lectin staining (brown) and myoblast engraftment was revealed by X-Gal 
staining (blue; n = 5–9/group). High VEGF levels caused the progressive growth of macroscopic angiomas (e) 
and required early termination of the experiment after 6 weeks (n = 4). Size bars = 20 μ m, except in (e): size 
bar = 1mm. (i) The amount of angiogenesis was quantified by measuring vessel length density (VLD) in areas of 
myoblast engraftment. Data are shown as mean  ±  SEM (n = 9–18 measurements/group in 5–9 tissues/group); 
****p < 0.0001 vs control (ANOVA with Sidak multiple comparisons test).
www.nature.com/scientificreports/
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homogeneous smooth-muscle coat17. While the angiogenic response to VEGF and PDGF-BB delivery was tightly 
localized around the expressing myoblasts, a large number of arterioles could be identified exclusively in the zone 
Figure 7. Maturation of capillaries induced by long-term co-expression of VEGF and PDGF-BB. V and VIP 
myoblasts clones, expressing low, medium or high levels, as well as control cells (Ctrl), were implanted into calf 
muscles of SCID mice. Frozen sections were obtained 4 months after implantation and immunostained for CD31 
(endothelium, in red), NG2 (pericytes, in green) and α -SMA (smooth muscle cells, in cyan); n = 3–7 samples/
group. In each panel, the right image is a higher-magnification view of the area marked by the white dotted box 
in the left image. High VEGF levels caused the progressive growth of macroscopic angiomas (f) and required 
early termination of the experiment after 9 weeks (n = 4). Size bars = 20 μ m, except in (f): size bar = 100 μ m; 
asterisks in (f) indicate large angioma-like aberrant vascular structures.
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of muscle fibers immediately adjacent to it (Fig. 9), as previously described with uncontrolled levels of VEGF 
alone17. All conditions that induced normal angiogenesis (V-low, V-med, VIP-low, VIP-med and VIP-high) also 
exhibited a significantly increased arteriole density in the peri-angiogenic areas compared to control muscles 
(Fig. 9g). Interestingly, the amount of induced arterioles was proportional to the VEGF dose, while co-expression 
of PDGF-BB did not affect their density further (Fig. 9g). Notably, the most abundant arteriole induction was 
observed in the VIP-high condition, reaching about double the density as in the V-low and VIP-low muscles. 
These results suggest that co-expression of VEGF and PDGF-BB induces physiologically organized vascular 
trees composed of both arterial and capillary compartments. Further, while PDGF-BB did not modify the VEGF 
dose-dependent generation of arterioles, it enabled the positive effect of higher VEGF doses by preventing angi-
oma formation.
Discussion
PDGF-BB co-expression is an attractive strategy to avoid side effects of uncontrolled VEGF delivery, with the goal 
of improving safety and efficacy of therapeutic angiogenesis. However, long-term expression, which may be nec-
essary to ensure stabilization and persistence of induced angiogenesis, raises safety concerns. Here we found that 
long-term co-expression of VEGF and PDGF-BB ensures completely normal and stable angiogenesis in the ther-
apeutic target tissue of skeletal muscle. PDGF-BB specifically prevented the appearance of aberrant angioma-like 
structures with high VEGF doses, instead yielding normal networks of mature capillaries, but did not affect the 
already normal angiogenesis induced by low and medium VEGF doses.
Both VEGF and PDGF-BB exhibit strong binding to extracellular matrix and exquisite localization in the 
microenvironment around each producing cell in vivo9,18. This binding leads to the formation of microenviron-
mental gradients of concentration, which are actually required for the biological function of both factors. In fact, 
seminal studies in transgenic mice that produce only one of the 3 major splice isoforms of VEGF, which differ in 
their affinity for extracellular matrix and therefore in their degree of diffusion and the shape of formed gradients, 
showed that balanced matrix binding is required to ensure proper vessel morphogenesis; whereas too little or 
too much of it resulted in dysfunctional vascular networks, displaying excessive enlargement or hyperbranching, 
respectively19. On the other hand, deletion of the matrix-retention motif from the endogenous Pdgfb gene, lead-
ing to free diffusion of the expressed protein, paradoxically caused detachment of pericytes from endothelium 
rather than their recruitment, and resulted in defective angiogenesis20.
Figure 8. Long-term myoblast engraftment. Myoblast engraftment was revealed by X-Gal staining (blue) on 
frozen sections of the same muscles analyzed in Fig. 7. Cell engraftment occurred only along the needle tracks of 
cell injections and all the conditions showed similar engraftment, except for the high VEGF condition (d), in which 
no myoblasts survived (n = 3–7 samples/group). Size bars = 200 μ m, except in (d): size bar = 400 μ m; asterisks in 
(d) indicate large angioma-like aberrant vascular structures.
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Figure 9. Arteriole formation adjacent to areas of angiogenesis. Capillaries and arterioles were identified by 
immunostaining on frozen sections of the same muscles analyzed in Figs 7 and 8, 4 months after implantation 
of control cells (Ctrl) or V and VIP myoblasts clones, expressing low, medium or high levels. (a–f) Endothelium 
is stained in red (CD31) and smooth muscle cells in cyan (α -SMA). In each panel, the right image is a higher-
magnification view of the area marked by the white dotted box in the left image. Size bars = 50 μ m in all panels. 
(g) Quantification of the number of arterioles adjacent to the areas of increased angiogenesis, which were 
strictly localized to the sites of myoblast engraftment. Data are shown as mean  ±  SEM (n = 14 measurements/
group in 2 tissues/group); ****p < 0.0001 vs control and for indicated comparisons; *p < 0.05 for indicated 
comparisons (ANOVA with Sidak multiple comparisons test).
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Direct gene transfer, such as with clinically employed viral vectors, leads to heterogeneous expression levels 
in the tissue and it is unsuitable to study the effects of specific factor doses localized in the microenvironment. 
Therefore, in order to rigorously investigate the dose-dependent effects of VEGF and PDGF-BB co-expression 
we took advantage of a highly controlled gene delivery platform, based on monoclonal populations of trans-
duced myoblasts10: since all cells in the implanted monoclonal populations share the same copy number and 
genomic integration sites of the retroviral vectors, the global effects in the muscles reflect the actions of a specific 
microenvironmental dose of each factor. Furthermore, we previously showed that the co-expression of VEGF and 
PDGF-BB from a single bicistronic vector ensures that both factors generate overlapping gradients around pro-
ducing cells in the tissue at balanced levels12. This is a key aspect to ensure consistent pericyte recruitment to the 
activated endothelial structures, as co-expression of PDGF-BB and VEGF from separate viral vectors led instead 
to their detachment from nascent vessels21.
While the normal angiogenesis induced by V-low and V-medium levels was not affected by PDGF-BB, the 
VIP-high condition a) restored vessel length density to the same level as lower VEGF doses, and b) yielded cap-
illary networks with diameters similar to the V-med and larger than V-low (Fig. 3b, p < 0.01). These results bear 
therapeutic relevance. In fact, using the same delivery platform we previously found that effective blood flow 
improvement in a hindlimb ischemia model required a combined increase in vessel number and size. Only the 
V-med clones effectively provided this optimal functional outcome, whereas similar amounts of equally nor-
mal, but smaller, vessels induced by the V-low clones could not improve tissue perfusion11. Therefore, PDGF-BB 
co-expression not only prevented the growth of angioma-like structures by high VEGF doses, but also yielded 
vascular networks with the morphometric characteristics required for efficacious functional improvement. In 
this respect, it should be noticed that the robust growth of normal microvascular capillary networks was also 
accompanied by the generation of numerous arterioles in the immediately adjacent areas. In fact, while increased 
capillary density can facilitate metabolic exchanges, functional improvement requires the generation of new arte-
rial vessels (arteriogenesis) to supply increased blood flow to the affected tissues22. Interestingly, we found that the 
amount of induced arterioles was directly dependent on VEGF dose. VEGF is known to favor arterial over venous 
differentiation and to be required for adult arteriogenesis23, but to our knowledge this is the first report showing 
that the arteriogenic effect of VEGF in adult skeletal muscle is dose-dependent. PDGF-BB did not show any 
direct arteriogenic function with low and medium VEGF levels. However, by preventing the growth of aberrant 
angioma-like vascular structures, PDGF-BB co-delivery with high doses of VEGF enabled the highest increase 
in arteriole density of all conditions, i.e. about double compared to V-low/VIP-low and six times the control 
values. These data lend further support to the concept that the therapeutic potential of VEGF may be expanded 
by increasing the safety of higher doses through PDGF-BB co-delivery. In agreement with these observations, 
co-expression of VEGF and PDGF-BB at uncontrolled levels has been previously found to significantly improve 
tissue perfusion in ischemic hind-limbs compared to VEGF alone12.
It is interesting to note that the results in Figs 3 and 6 show how all conditions that lead to normal angiogene-
sis, whether by VEGF alone or together with PDGF-BB co-expression, induced a remarkably similar increase in 
vessel length density of slightly less than 2-fold compared to controls. A possible explanation for this similarity in 
the amount of induced angiogenesis, despite very different factor doses, may be provided by our recent finding 
that VEGF over-expression in skeletal muscle, at the doses required for functional benefit, does not cause vascu-
lar growth by the well-known process of sprouting, but rather through an initial circumferential enlargement of 
pre-existing vessels followed by longitudinal splitting into two new capillaries, i.e. intussusceptive angiogenesis16. 
As this process essentially leads to a stereotyped doubling of vessels in affected areas, it is tempting to speculate 
that PDGF-BB co-expression may normalize VEGF-induced aberrant angiogenesis by regulation of intussuscep-
tive vascular growth. This hypothesis remains to be investigated by ad hoc experiments.
A particularly relevant finding from a clinical point of view is that balanced co-expression of VEGF and 
PDGF-BB from a single vector ensured the long-term safety and stability of induced angiogenesis. Notably, not 
only did the balanced co-expression prevent the appearance of aberrant angiogenesis by 4 weeks, but also stably 
avoided the emergence of even microscopic angioma-like structures for up to 4 months, despite the delivery 
of high VEGF levels. This is in sharp contrast to the induction of aberrant vessels by similar levels of VEGF 
alone within 4 weeks, which progressively grew into macroscopic and life-threatening hemangiomas already by 
6 weeks, requiring termination of the experiment. It is interesting to note that aberrant structures induced by high 
VEGF alone continued growing into macroscopic angiomas between 4 and 9 weeks despite disappearance of the 
V-high myoblasts (Fig. 8d), in agreement with previous observations with both clonal and polyclonal populations 
of VEGF-expressing myoblasts10, indicating that high VEGF levels are only required in the early stages of aber-
rant angiogenesis, which then becomes a self-sustaining process. The underlying mechanism remains to be fully 
elucidated. However, blockade experiments indicate that sustained angioma growth still depends on VEGF sig-
nalling, likely from endogenous sources. In fact, in experiments with the same myoblast-based delivery platform, 
VEGF sequestration by treatment with the receptor-body Aflibercept (VEGF-Trap) caused aberrant angiogenesis 
to regress both after 2, 3 and 4 weeks, when implanted V-high myoblasts had already disappeared and could no 
longer provide VEGF production, whereas normal angiogenesis induced by lower VEGF levels had completely 
stabilized by 4 weeks and could persist despite VEGF blockade10,24.
The use of monoclonal myoblast populations, in which every cell produces the same levels of VEGF and 
PDGF-BB, excludes the possibility that the observed phenotypic conversion from angioma-like vascular struc-
tures to normal capillary networks could be due to a selection of subpopulations producing optimal VEGF levels. 
Furthermore, the analysis of in vivo expression levels also excludes the possibility that the angiogenic normaliza-
tion could be due to a down-regulation of VEGF expression by PDGF-BB, as the transcripts for both exogenous 
(retroviral vector-encoded) and endogenous VEGF were similar or higher in the tissues implanted with VIP 
clones compared to the corresponding V clones. The analysis was focused on the first week after implantation 
because it has been previously determined that the transition between normal and aberrant angiogenesis by 
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increasing VEGF doses crucially takes place during the initial morphogenic events in a well-defined time window 
between 4 and 7 days after factor delivery16.
Therapeutic efficacy depends not only on the efficient induction of normal and functional vascular networks, 
but also on their long-term persistence. It is therefore important that vessel length density quantifications showed 
that the amount of induced angiogenesis remained stable between 4 weeks and 4 months, retaining the features of 
mature vasculature, associated with normal NG2-positive pericytes that established tight cell-to-cell contacts with 
the endothelium25,26. On the other hand, stabilization and persistence of newly induced vessels is not exclusively 
regulated by the PDGF-BB/pericyte axis27. For example, Angiopoietin-1, which is normally secreted by pericytes 
and activates its endothelial receptor Tie2, has been shown to restore the vascular defects caused by pericyte 
ablation in the retina, stabilizing vessels and preventing edema and hemorrhage despite the persistent absence 
of mural cells28. Also inflammatory cells of different origin significantly contribute to vascular stabilization and 
persistence, such as pro-angiogenic CXCR4 + myeloid cells29 or Neuropilin1-expressing monocytes that produce 
several vascular maturation factors and can be recruited by endothelial Semaphorin3A24,30. The regulation of 
recruitment and function of pro-maturative myeloid populations by PDGF-BB remains to be investigated.
In conclusion this study shows that VEGF and PDGF-BB co-expression by a single bicistronic construct pro-
motes long-lasting and safe angiogenesis in a mouse model, suggesting that this approach may have promising 
potential to overcome challenges of VEGF gene therapy. It should be underlined that the use of monoclonal 
populations of transduced myoblasts would not be directly employable in a clinical setting, but rather provides 
controlled conditions for a proof-of-concept, which should be translated towards a clinical application using 
other gene delivery platforms, such as AAV vectors. On the other hand, the library of monoclonal populations 
described here provides a highly standardized platform for future studies to investigate the cellular and molecular 
mechanisms controlling the switch between normal and aberrant angiogenesis by VEGF dose and its regulation 
by pericyte recruitment.
Methods
Cell culture. Primary myoblasts isolated from C57BL/6 mice and transduced to express the β -galactosidase 
marker gene (lacZ) from a retroviral promoter31 were over-infected at high efficiency32 with the retroviruses 
expressing murine VEGF164, human PDGF-BB, or both at a fixed ratio to each other from a bicistronic cassette 
through the encephalomyocarditis virus Internal Ribosomal Entry Site (IRES) as previously described12. A trun-
cated version of CD8a (trCD8a) was co-expressed with VEGF or PDGF-BB from a similar bicistronic cassette 
(V and P), or from a separate promoter (VIP), as a convenient cell surface marker of transduced cells, as 
described15. Single cells were isolated from the resulting V, P and VIP (Vegf-Ires-Pdgfb) transduced populations 
by FACS, based on their CD8 staining, using a Vantage SE cell sorter (Becton Dickinson, Basel, Switzerland). 
Single cell isolation was confirmed visually and monoclonal populations of transduced myoblasts were expanded 
in culture to express specific and homogeneous levels of each factor, as previously described10,11,15. All myoblast 
populations were cultured in 5% CO2 on collagen-coated dishes, with a growth medium consisting of 40% F10, 
40% DMEM low glucose (1000 mg glucose/L) (Sigma-Aldrich Chemie GmbH, Steinheim, Germany) and 20% 
fetal bovine serum (HyClone, Logan, UT) supplemented with 2.5 ng/ml basic fibroblast growth factor (FGF-2) 
(Becton Dickinson, Basel, Switzerland), as described33.
VEGF164 and PDGF-BB ELISA measurements. Cell culture supernatants were quantified for mVEGF164 
and hPDGF-BB protein using an ELISA kit (R&D Systems Europe, Abingdon, UK). The stability of VEGF and 
PDGF-BB secretion was assessed periodically during in vitro expansion of different cell batches. One ml of 
medium was harvested from myoblasts cultured in one 60 mm dish, following a 4-hour incubation, filtered and 
analyzed in duplicate. Medium was supplemented with 10 μ g/ml heparin to prevent retention of PDGF-BB on the 
cell surface. Results were normalized for the number of cells and time of exposure to medium. Four dishes of cells 
were assayed for each clone, which was used for in-vivo experiments (n = 4).
In vivo myoblast implantation. In order to avoid an immunological response to engineered myoblasts 
that express β -galactosidase and hPDGF-BB, 6–8 week-old immunodeficient SCID CB. 17 mice (Charles River 
Laboratories, Sulzfeld, Germany) were used. Animals were treated in accordance with the Swiss Federal guidelines 
for animal welfare, after approval from the Veterinary Office of the Canton of Basel-Stadt (Basel, Switzerland). 
Myoblasts were dissociated in trypsin and resuspended in PBS with 0.5% BSA. 5 × 105 myoblasts in 5 μ l were 
implanted into the posterior auricular muscle, midway up the dorsal aspect of the external ear, and into the tibialis 
anterior and gastrocnemius muscles in the calf, using a syringe with a 30-gauge needle.
Tissue staining. The entire vascular network of the ear could be visualized following intravascular staining 
with a biotinylated Lycopersicon esculentum lectin (Vector Laboratories, Burlingame, CA) that binds the lumi-
nal surface of all blood vessels, as previously described10. Mice were anesthetized by i.p. injection of Ketamine 
(100 mg/kg) and Xylazin (10 mg/kg), lectin was injected intravenously (100 μ l per mouse of lectin at 1 mg/ml 
concentration) and 4 minutes later the tissues were fixed by vascular perfusion of 1% paraformaldehyde and 
0.5% glutaraldehyde in PBS pH 7.4. Ears were then removed, bisected in the plane of the cartilage, and stained 
with X-gal staining buffer (1 mg/ml 5-bromo-4-chloro-3-indoyl-β -D-galactoside, 5 mM potassium ferricy-
anide, 5 mM potassium ferrocyanide, 0.02% Nonidet P-40, 0.01% sodium deoxycholate, 1 mM MgCl2 in PBS 
pH 7.4). Tissues were stained using avidin-biotin complex-diaminobenzidine histochemistry (Vector 
Laboratories, Burlingame, CA), dehydrated through an alcohol series, cleared with toluene and whole-mounted 
on glass slides with Permount embedding medium (Fisher Scientific, Wohlen, Switzerland). For tissue sections, 
mice were anesthetized as above, sacrificed by cervical dislocation and the entire tibialis anterior and gastrocne-
mius muscles or whole ears were harvested, embedded in OCT compound (Medite, Basel, Switzerland), frozen 
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in freezing isopentane and cryosectioned. Alternatively, mice were anesthetized and the tissues were fixed by 
vascular perfusion of 1% paraformaldehyde in PBS pH 7.4 for 3 minutes. Entire tibialis anterior and gastrocne-
mius muscles excised from perfused mice were fixed for additional two hours in 0.5% paraformaldehyde and 
then immersed overnight in 30% sucrose solution for cryoprotection before being embedded in OCT compound 
and frozen. Tissue sections were then stained with X-gal (20 μ m sections) or with H&E (10 μ m sections) as previ-
ously described31,32. Immunofluorescence was performed as previously described10. The following primary anti-
bodies and dilutions were used: rat monoclonal anti-mouse PECAM-1 (clone MEC13.3, BD Biosciences, Basel, 
Switzerland) at 1:100; mouse monoclonal anti-mouse α -SMA (clone 1A4, MP Biomedicals, Basel, Switzerland) 
at 1:400; rabbit polyclonal anti-NG2 (Chemicon International, Hampshire, UK) at 1:200. Fluorescently labeled 
secondary antibodies (Invitrogen, Basel, Switzerland) were used at 1:200.
Vessel measurements. Vessel length density (VLD) and diameters were measured in whole mounts of ears 
stained with L. esculentum lectin as previously described10. Briefly, vessel diameters were measured by overlaying 
a captured microscopic image with a square grid. Squares were chosen at random, and the diameter of each vessel 
(if any) in the center of selected squares was measured. Two hundred total vessel diameter measurements were 
obtained from 6−10 ears per each group (n = 6–10). Vessel length density was measured on 1 to 3 fields per ear in 
6–10 ears per each group (n = 6–10) by tracing the total length of vessels in the fields and dividing it by the area 
of the fields. All image measurements were performed with AnalySIS D software (Soft Imaging System, Gmbh, 
Münster, Germany). The number of arterioles was quantified in fluorescently immunostained cryosections. 
Briefly, arterioles were defined as vessels of regular shape and moderately larger than capillaries (15–30 μ m) asso-
ciated with a thick and homogeneous smooth muscle layer (positive for α -smooth muscle actin, α -SMA) coating 
the endothelial layer (positive for CD31), as previously described17, and were counted on 14 microscopic fields/
group, localized in proximity to the areas of induced angiogenesis (n = 2 muscles/group; field size = 180′ 710 μ m2).
Quantitative Real Time-PCR. Whole fresh mouse muscles were disrupted using a Qiagen Tissue Lyser 
(Qiagen, Hombrechtikon, Switzerland) to extract total RNA with a commercial kit (Qiagen, Hombrechtikon, 
Switzerland), according to the manufacturer’s instructions (n =  4 muscles per group). Total RNA was 
reverse-transcribed into cDNA with the Omniscript Reverse Transcription kit (Qiagen, Hombrechtikon, 
Switzerland) at 37 °C for 60 minutes. Quantitative Real-Time PCR (qRT-PCR) was performed on an ABI 7300 
Real-Time PCR system (Applied Biosystems, Zug, Switzerland). In order to quantify mouse VEGF164 transcripts 
from the transduced myoblasts Specific sets of primer and probe sequences were designed with Primer Express soft-
ware 3.0 (Applied Biosystems, Zug, Switzerland) to quantify mouse VEGF164 transcripts from the exogenous trans-
duced myoblasts (Exo), based on a sequence expressed by the VEGF retroviral construct, or from the endogenous 
gene (Endo): Exo V-forward: 5′ -GCTCTCCTCAAGCGTATTCAACA; Exo V-reverse: 5′ -CCCCAGATCAGA 
TCCCATACA;  Exo V-prob e :  5 ′  -FAM-CTGAAGGATGCCCAGAAGGTACCCCA-TAMRA; 
Endo V-forward: 5′ -GACGGGCCTCCGAAACC; Endo V-reverse: 5′ -TGGTGGAGGTACAGCAGTAAAGC; 
Endo V-probe, 5′ -FAM-AACTTTCTGCTCTCTTGGGTGCACTGGAC-TAMRA.
To determine the expression of the other genes the following TaqMan gene expression assays were used from 
Applied Biosystems (Applied Biosystems, Zug, Switzerland): murine Pdgfb (Mm00440678_s1), human Pdgfb 
(Hs00234042_m1) and murine Gapdh housekeeping gene (Mm03302249_g1). The cycling parameters were: 
50 °C for 2 minutes, followed by 95 °C for 10 minutes and 40 cycles of denaturation at 95 °C for 15 seconds and 
annealing/extension at 60 °C for 1 minute. All primers were used at 400nM, except the Endo-V probe at 100nM. 
Reactions were performed in triplicate for each template, averaged, and normalized to expression of the Gapdh 
housekeeping gene.
Statistics. Data are presented as means ± standard error. The significance of differences was evaluated with 
the GraphPad Prism 6 software (GraphPad Software). Multiple comparisons were performed using analysis of 
variance (ANOVA) followed by the Sidak test. Gene expression data representing fold-changes versus control, 
which are asymmetrically distributed, were first normalized by logarithmic ln(y) transformation and then ana-
lyzed by 1-way ANOVA followed by the Sidak test for multiple comparisons; p < 0.05 was considered statistically 
significant.
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